Nanomedicine: An effective tool in cancer therapy

Aftab, Saima; Shah, Afzal; Nadhman, Akhtar; Kurbanoğlu, Sevinç; Özkan, Síbel A.; Dionysiou, Dionysios D.; Shukla, Shyam S.; Aminabhavi, Tejraj M.

doi:10.1016/j.ijpharm.2018.02.007

Cited by 179 publications

(105 citation statements)

References 201 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…These properties have been exploited to create effective therapeutic and/or diagnostic tools [8, 9]. Nanomaterials can be used as cytotoxics, and/or enhancers of standard chemotherapies, as well as, drug delivery systems, reducing the side effects of conventional drugs [10, 11]. A number of nanomedicines have been assessed in clinical trials in combination with various therapeutic agents, mainly anticancer drugs, and many more are expected to be approved by the Food and Drug Administration (FDA) in the near future [12, 13].…”

Section: Introductionmentioning

confidence: 99%

Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment

Cordani

Somoza

2018

Cell. Mol. Life Sci.

150

105

View full text Add to dashboard Cite

Despite the extensive genetic and phenotypic variations present in the different tumors, they frequently share common metabolic alterations, such as autophagy. Autophagy is a self-degradative process in response to stresses by which damaged macromolecules and organelles are targeted by autophagic vesicles to lysosomes and then eliminated. It is known that autophagy dysfunctions can promote tumorigenesis and cancer development, but, interestingly, its overstimulation by cytotoxic drugs may also induce cell death and chemosensitivity. For this reason, the possibility to modulate autophagy may represent a valid therapeutic approach to treat different types of cancers and a variety of clinical trials, using autophagy modulators, are currently employed. On the other hand, recent progress in nanotechnology offers plenty of tools to fight cancer with innovative and efficient therapeutic agents by overcoming obstacles usually encountered with traditional drugs. Interestingly, nanomaterials can modulate autophagy and have been exploited as therapeutic agents against cancer. In this article, we summarize the most recent advances in the application of metallic nanostructures as potent modulators of autophagy process through multiple mechanisms, stressing their therapeutic implications in cancer diseases. For this reason, we believe that autophagy modulation with nanoparticle-based strategies would acquire clinical relevance in the near future, as a complementary therapy for the treatment of cancers and other diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment

Cordani

Somoza

2018

Cell. Mol. Life Sci.

150

105

View full text Add to dashboard Cite

show abstract

“…Therefore, we developed a formulation of NLC, which represents a good strategy for FA delivery due to the small particles size and high homogeneity, the high long-term stability, the good systemic tolerability, the high encapsulation efficiency and controlled drug release properties 34,47,48 . To obtain NLC for the glioblastoma treatment, glyceryl oleate was selected for its bioadhesive properties which together with the well-known role of brij components in increasing drug targeting to the CNS, could enhance nanoparticles crossing through the BBB and selectively destroy tumour cells 49,50 . As reported in different articles, brij-decorated nanoparticles have been demonstrated to increase drug targeting to CNS [51][52][53][54] .…”

Section: Discussionmentioning

confidence: 99%

Synergic pro-apoptotic effects of Ferulic Acid and nanostructured lipid carrier in glioblastoma cells assessed through molecular and Delayed Luminescence studies

Grasso

Dell’Albani

Carbone

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Herein, we assessed the effect of Ferulic Acid (FA), a natural antioxidant with anti-cancer effect, on the human glioblastoma cells through molecular and Delayed Luminescence (DL) studies. DL, a phenomenon of ultra-week emission of optical photons, was used to monitor mitochondrial assessment. The effect of FA loaded in nanostructured lipid carriers (NLCs) was also assessed. To validate NLCs as a drug delivery system for glioblastoma treatment, particular attention was focused on their effect. We found that free FA induced a significant decrease in c-Myc and Bcl-2 expression levels accompanied by the apoptotic pathway activation. Blank NLCs, even if they did not induce cytotoxicity and caspase-3 cleavage, decreased Bcl-2, ERK1/2, c-Myc expression levels activating PARP-1 cleavage. The changes in DL intensity and kinetics highlighted a possible effect of nanoparticle matrix on mitochondria, through the involvement of the NADH pool and ROS production that, in turn, activates ERK1/2 pathways. All the effects on protein expression levels and on the activation of apoptotic pathway appeared more evident when the cells were exposed to FA loaded in NLCs. We demonstrated that the observed effects are due to a synergic pro-apoptotic influence exerted by FA, whose bioavailability increases in the glioblastoma cells, and NLCs formulation.Glioblastoma multiforme (GBM), also known as grade IV astrocytoma, represents the most prevalent and aggressive brain cancer. It is characterized by glial cells and has finger-like tentacles that infiltrate the brain, which make them very difficult to remove with surgical procedures. GBM exhibits a high level of resistance to conventional chemotherapy and radiotherapy, also due to the existence of blood-brain barrier (BBB), glioma stem cells and complex network of multiple modified signalling pathways 1 . The most frequent aberrant expression is represented by the dysregulation of extracellular signal-regulated protein kinase (ERK), which is associated with poor survival of the patients. The ERK isoforms (p42/44 or ERK1/ERK2) by interacting with specific phosphorylation substrates, play a pivotal role in the control of several cellular processes involved in proliferation, as well as activation of transcription factors, apoptosis and the control of cellular process 2,3 . In addition, the transcription factor c-Myc has been recognized as an important regulator of stem cell biology implicated with GBM malignancy and stemness 4 , as it contributes to proliferation, growth and survival of GBM stem cells 5 . GBM has been also related to the impairment of mitochondrial metabolic capacity, which leads to the alteration in energy production 6,7 and is characterized by an overexpression of Bcl-2 8 . This protein can regulate transition pores permeability of the outer mitochondrial membrane and block pro-apoptotic proteins 9 . Furthermore, it has been identified a novel www.nature.com/scientificreports www.nature.com/scientificreports/ interaction between Bcl-2 and (ADP-ribose) polymerase (PARP) 10 , t...

show abstract

“…The development of nanomaterial‐based drug delivery systems holds the potential to overcome these limitations by targeting the chemotherapies locally at optimal concentration and reducing the cytotoxicity and side‐effects to non‐malignant cells . The strategy which was the most extensively explored to selectively address nanomaterials at cancer lesions is based on passive targeting resulting from the enhanced permeability and retention (EPR) effect through the non‐structured blood vessels which grow concomitantly to cancer cell invasion and tumor development . Actively targeted nanocarriers make use of surface functionalization with targeting ligands addressing biomarkers which are overexpressed or specifically expressed by cancer cells and cancer associated fibroblasts .…”

Section: Introductionmentioning

confidence: 99%

Photocontrolled Release of the Anticancer Drug Chlorambucil with Caged Harmonic Nanoparticles

Vuilleumier

Gaulier

Matos

et al. 2020

Helvetica Chimica Acta

View full text Add to dashboard Cite

Dedicated to Philippe Renaud on the occasion of his 60th birthdayWhile chemotherapy is one of the most used treatments in oncology, the systemic administration of chemotherapeutics generally results in undesired damages to healthy tissues and cells, side effects such as severe nausea and leukopenia, and reduced efficacy due to multidrug resistance and poor target accessibility. The limitations of conventional chemotherapy formulation have prompted the development of alternative nanomaterials-based strategies to achieve targeted and stimuli sensitive payload delivery to reach optimal local drug concentration at tumor sites. In this study, the anticancer drug chlorambucil (Clb) was conjugated to the surface of silica coated lithium niobate (LNO) harmonic nanoparticles (HNPs) using a photocaging tether based on coumarin-4-yl methyl derivative. Upon laser pulsed femtosecond irradiation at 790 nm, the second harmonic emission from the metal oxide core induced the efficient release of Clb, with concomitant contribution from the nonlinear absorption of the coumarin (CM)-based moiety.

show abstract

Nanomedicine: An effective tool in cancer therapy

Cited by 179 publications

References 201 publications

Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment

Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment

Synergic pro-apoptotic effects of Ferulic Acid and nanostructured lipid carrier in glioblastoma cells assessed through molecular and Delayed Luminescence studies

Photocontrolled Release of the Anticancer Drug Chlorambucil with Caged Harmonic Nanoparticles

Contact Info

Product

Resources

About